LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

433.1 -0.04

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

432.05

Максимум

438.16

Ключови измерители
By Trading Economics
Приходи	-160M 1B
Продажби	-240M 3B
P/E Средно за сектора	25.91 49.701
EPS	4.47
Марж на печалбата	34.531
Служители	6,400
EBITDA	-215M 1.1B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+29.84% upside

Дивиденти
By Dow Jones
Следващи печалби	3.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.4B 111B
Предишно отваряне	433.14
Предишно затваряне	433.1

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

428.545 / 498.65 Подкрепа & съпротива

Vertex Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.05.2026 г., 20:57 ч. UTC

Печалби

Vertex Pharmaceuticals Posts Higher 1Q Profit

12.02.2026 г., 21:47 ч. UTC

Печалби

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3.11.2025 г., 21:44 ч. UTC

Печалби

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5.08.2025 г., 00:05 ч. UTC

Горещи акции

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4.08.2025 г., 21:21 ч. UTC

Печалби

Значими двигатели на пазара

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4.08.2025 г., 20:45 ч. UTC

Печалби

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4.05.2026 г., 20:02 ч. UTC

Печалби

Vertex Pharmaceuticals Reiterates 2026 Guidance

4.05.2026 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4.05.2026 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4.05.2026 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4.05.2026 г., 20:01 ч. UTC

Печалби

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12.02.2026 г., 21:13 ч. UTC

Печалби

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12.02.2026 г., 21:13 ч. UTC

Печалби

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12.02.2026 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12.02.2026 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12.02.2026 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12.02.2026 г., 21:01 ч. UTC

Печалби

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3.11.2025 г., 21:05 ч. UTC

Печалби

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3.11.2025 г., 21:02 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3.11.2025 г., 21:02 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3.11.2025 г., 21:02 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3.11.2025 г., 21:02 ч. UTC

Печалби

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5.08.2025 г., 20:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 18:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5.08.2025 г., 15:25 ч. UTC

Печалби

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5.08.2025 г., 14:12 ч. UTC

Печалби

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5.08.2025 г., 11:27 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:55 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:36 ч. UTC

Печалби

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5.08.2025 г., 10:18 ч. UTC

Печалби

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Vertex Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

29.84% нагоре

12-месечна прогноза

Среден 562.9 USD 29.84%

Висок 641 USD

Нисък 436 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за Vertex Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

24 ratings

Купи

Задържане

Продай

Според 24 анализатори, дали борсови рейтинги на Vertex Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

428.545 / 498.65Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.